Benefit with anti-PD-L1

被引:0
|
作者
Diana Romero
机构
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:71 / 71
相关论文
共 50 条
  • [41] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
    Borch, Troels H.
    Donia, Marco
    Andersen, Mads H.
    Svane, Inge M.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1127 - 1134
  • [42] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
  • [43] Development of novel combination cancer immunotherapy using anti-PD-1 and anti-PD-L1 antibody
    Hasegawa, Hirotaka
    Sugiyama, Daisuke
    Kanda, Mitsuro
    Hayashi, Masamichi
    Tanaka, Chie
    Yamada, Suguru
    Nakayama, Goro
    Koike, Masahiko
    Nomoto, Shuji
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    Nishikawa, Hiroyoshi
    CANCER SCIENCE, 2021, 112 : 741 - 741
  • [44] Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies
    Heskamp, Sandra
    Hobo, Willemijn
    Molkenboer-Kuenen, Janneke D. M.
    Olive, Daniel
    Oyen, Wim J. G.
    Dolstra, Harry
    Boerman, Otto C.
    CANCER RESEARCH, 2015, 75 (14) : 2928 - 2936
  • [45] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [46] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
    Sun, J.
    Yang, Q.
    Chen, M.
    Gu, J.
    Zheng, L.
    Yu, Y.
    Li, F.
    Zhang, L.
    Niu, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S134 - S135
  • [47] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
  • [48] DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC
    Wei, Jinhuan
    Lu, Jun
    Cao, Yun
    Yao, Gaosheng
    Huang, Yong
    Zhao, Hongwei
    Pan, Yihui
    Feng, Zihao
    Chen, Zhenhua
    Chen, Wei
    Luo, Junhang
    Cao, Jiazheng
    CURRENT CANCER DRUG TARGETS, 2021, 21 (10) : 849 - 859
  • [49] Early predictive factors and biomarkers for the response to immunological checkpoint inhibitors (anti-PD-1 and anti-PD-L1)
    Colle, E.
    Andre, T.
    Lebbe, C.
    Borg, C.
    ONCOLOGIE, 2016, 18 (9-10) : 533 - 542
  • [50] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143